121 related articles for article (PubMed ID: 8757576)
1. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.
Kaplan P; Mazur A; Manor O; Charrow J; Esplin J; Gribble TJ; Wappner RS; Wisch JS; Weinreb NJ
J Pediatr; 1996 Jul; 129(1):149-53. PubMed ID: 8757576
[TBL] [Abstract][Full Text] [Related]
2. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
3. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
5. Type I Gaucher disease in children with and without enzyme therapy.
Dweck A; Abrahamov A; Hadas-Halpern I; Bdolach-Avram T; Zimran A; Elstein D
Pediatr Hematol Oncol; 2002 Sep; 19(6):389-97. PubMed ID: 12186361
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?
Biasucci G; Manfredi P
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S51-4. PubMed ID: 20049531
[TBL] [Abstract][Full Text] [Related]
7. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
8. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
9. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
Aviner S; Levy Y; Yaniv I; Cohen IJ
Blood Cells Mol Dis; 1999 Apr; 25(2):92-4. PubMed ID: 10389590
[TBL] [Abstract][Full Text] [Related]
10. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
11. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy.
Zevin S; Abrahamov A; Hadas-Halpern I; Kannai R; Levy-Lahad E; Horowitz M; Zimran A
Q J Med; 1993 Sep; 86(9):565-73. PubMed ID: 8255971
[TBL] [Abstract][Full Text] [Related]
12. Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.
Ciana G; Deroma L; Franzil AM; Dardis A; Bembi B
J Inherit Metab Dis; 2012 Nov; 35(6):1101-6. PubMed ID: 22441841
[TBL] [Abstract][Full Text] [Related]
13. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
Whittington R; Goa KL
Pharmacoeconomics; 1995 Jan; 7(1):63-90. PubMed ID: 10155294
[TBL] [Abstract][Full Text] [Related]
14. Alglucerase treatment of type 1 Gaucher disease with pulmonary involvement.
Martinez Odrizola P; Ferrero O; Jauregui I; Miguel F
Respir Med; 1998 Dec; 92(12):1370-2. PubMed ID: 10197233
[No Abstract] [Full Text] [Related]
15. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
16. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
Grabowski GA; Kacena K; Cole JA; Hollak CE; Zhang L; Yee J; Mistry PK; Zimran A; Charrow J; vom Dahl S
Genet Med; 2009 Feb; 11(2):92-100. PubMed ID: 19265748
[TBL] [Abstract][Full Text] [Related]
18. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients.
Zimran A; Hollak CE; Abrahamov A; van Oers MH; Kelly M; Beutler E
Blood; 1993 Aug; 82(4):1107-9. PubMed ID: 8353277
[TBL] [Abstract][Full Text] [Related]
19. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient.
Aporta Rodriguez R; Escobar Vedia JL; Navarro Castro AM; Aguilar García G; Cabrera Torres A
Haematologica; 1998 Sep; 83(9):852-3. PubMed ID: 9825582
[TBL] [Abstract][Full Text] [Related]
20. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
